Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
- PERUSE investigators
- , D. Miles*
- , E. Ciruelos
- , A. Schneeweiss
- , F. Puglisi
- , T. Peretz-Yablonski
- , M. Campone
- , I. Bondarenko
- , Z. Nowecki
- , H. Errihani
- , S. Paluch-Shimon
- , A. Wardley
- , J. L. Merot
- , P. Trask
- , Y. du Toit
- , C. Pena-Murillo
- , V. Revelant
- , D. Klingbiel
- , T. Bachelot
- , K. Bouzid
*Korrespondierende/r Autor/-in für diese Arbeit
- East and North Hertfordshire NHS Trust
- University Hospital HM Hospitales
- Ruprecht-Karls-Universität Heidelberg
- University of Udine
- Hebrew University of Jerusalem
- Institut de Cancérologie de l'Ouest
- City Clinical Hospital No. 4
- Mohammed V Rabat University
- Chaim Sheba Medical Center Israel
- National Institute for Health and Care Research
- QuintilesIMS
- Genentech Incorporated
- Pharma Research and Early Development (pRED)
- Centre Leon Berard
91
!!Link opens in a new tab
Zitate
(Scopus)